FindTrial
Sign In

Single dose Rituximab in steroid dependent nephrotic syndrome and frequently relapsing nephrotic syndrome in children 2-18 years of age during a period of 1 year

Single dose Rituximab in steroid dependent nephrotic syndrome and frequently relapsing nephrotic syndrome in children 2-18 years of age in a tertiary care hospital during a period of 1 year - A pre post study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/054906
Enrollment
21
Registered
2023-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes

Interventions

None listed

Sponsors

Jawaharlal Nehru Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children with Steroid dependent nephrotic syndrome and frequently relapsing nephrotic syndrome

Exclusion criteria

Exclusion criteria: Children with Steroid resistant nephrotic syndrome Children with Chronic kidney disease Children who have already received Rituximab within last 1 year Children who are on Cyclosporin and on other calcineurin inhibitors

Design outcomes

Primary

MeasureTime frame
To assess sustained remission at 3 months post single dose rituximab in patients with steroid dependent nephrotic syndrome & frequently relapsing nephrotic syndromeTimepoint: The study will be conducted over a span of one year—

Secondary

MeasureTime frame
To assess B cell suppression by measuring CD19 levels just prior to rituximab then at 3 weeks & 3 months post single dose rituximab To predict relapse by assessing for recovery of B cell at 3 weeks and at 3 months post single dose rituximabTimepoint: 1 year—

Countries

India

Contacts

Public ContactDr Kavina Shah

KLES Dr Prabhakar Kore hospital

patilmv1@gmail.com9483561674

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026